Sullivan Aids Amgen On $315M Kidney Drugmaker Buy
Amgen said it will acquire San Francisco-based KAI in an all-cash transaction.
Under the terms of the agreement, Amgen will provide a loan to enable the third phase of clinical development for KAI's leading drug candidate KAI-4169, which treats secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis.
In return, Amgen will acquire...
To view the full article, register now.